GHHealthcare · Diagnostics & ResearchThe 26 Wall Street analysts covering Guardant Health, Inc. hold a median 12-month price target of $203 — +9.5% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 57 of 100 as at 28 Oct 2026 — in the upper half.
Consensus tells you what everyone already believes. The model scores Guardant Health, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.
Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested
Momentum (100): The shares have been drifting up relative to others.
Issuance (13): The company has been issuing shares or taking on financing, diluting existing holders.
Size (9): Larger than most of the companies we track — more scrutinised, less often mispriced.
Built and run by Aslam Ghouse, an ex-Goldman Sachs systematic trader with 15+ years in markets.
The bullish and bearish analyst opinions on GH, reported as data — targets and ratings, the market's view beside the model's.
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Data provided by Twelve Data
The green dot is the last close — the median target sits +9.5% from it.
Of the 20 most recent actions, 8 moved their price target up and 0 moved it down.
| Date | Firm | Action | Rating | Target |
|---|---|---|---|---|
| 27 Oct 2026 | BTIG | Maintains | Buy | $195 → $210 |
| 23 Oct 2026 | Roth Capital | Initiates | Buy | $200 |
| 13 Oct 2026 | Morgan Stanley | Maintains | Overweight | $185 → $200 |
| 13 Oct 2026 | Morgan Stanley | Maintains | Overweight | — |
| 7 Oct 2026 | Barclays | Maintains | Overweight | $200 → $220 |
| 7 Oct 2026 | Barclays | Maintains | Overweight | — |
| 1 Oct 2026 | Guggenheim | Maintains | Buy | $190 → $200 |
| 1 Oct 2026 | Guggenheim | Maintains | Buy | — |
| 9 Sept 2026 | UBS | Maintains | Buy | — |
| 9 Sept 2026 | UBS | Maintains | Buy | $175 → $225 |
| 8 Sept 2026 | Rothschild & Co | Initiates | Buy | $203 |
| 8 Sept 2026 | Rothschild & Co | Initiates | Buy | — |
| 2 Sept 2026 | BTIG | Reiterates | Buy | $195 |
| 2 Sept 2026 | BTIG | Reiterates | Buy | — |
| 4 Aug 2026 | Morgan Stanley | Maintains | Overweight | — |
| 4 Aug 2026 | Morgan Stanley | Maintains | Overweight | $175 → $185 |
| 4 Aug 2026 | Piper Sandler | Maintains | Overweight | $135 → $193 |
| 4 Aug 2026 | Piper Sandler | Maintains | Overweight | — |
| 4 Aug 2026 | Stephens & Co. | Maintains | Overweight | — |
| 4 Aug 2026 | Stephens & Co. | Maintains | Overweight | $170 → $195 |
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
GH appears in the Radar on the weeks it earns a place.
AI cloud capacity
MSFTAMZNGOOGLORCL
AI chips
NVDAAVGOAMDMU
AI networking and serversIn full
ANETDELLLITECRDO
Data centre power
VRTCEGGEVVST
Both lines are total return — dividends reinvested — so the comparison is honest on both sides.
Over the twelve months to 29 Oct 2026, Guardant Health, Inc. returned +156.4% against +13.1% for the S&P 500, dividends included.
Download this chart as an image — free to reuse; link this page as the source.
Data provided by Twelve Data
Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.
A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.
Cheaper than 99% of US stocks
Cheaper than 9% of US stocks
Cheaper than 99% of US stocks
Cheaper than 95% of US stocks
Higher than 84% of US stocks
Higher than 73% of US stocks
Higher than 79% of US stocks
Higher than 18% of US stocks
Higher than 12% of US stocks
Higher than 99% of US stocks
Higher than 21% of US stocks
Higher than 1% of US dividend payers
Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.
The headline figures, each with its date. Every row carries its own link — cite it straight from here.
Guardant Health, Inc. has a market value of $23.9B and an enterprise value of $24.5B.
Revenue in the twelve months to 30 June 2026: $1.2B. The latest quarter grew 44.3% year on year.
Net income over the same four quarters: −$453.4M, a −38.3% net margin.
Diluted earnings per share, trailing twelve months: $−3.49.
Free cash flow in the twelve months to 30 June 2026: −$240.7M.
Guardant Health, Inc. spent $0.0 on share buybacks in the twelve months to 30 June 2026.
Trailing P/E: −55.2×; forward P/E: −469.6× — the forward figure prices analyst consensus estimates, not reported earnings.
Forward dividend yield: 0.00%, paying out 0% of earnings.
Guardant Health, Inc. employs 2,490 people — $475K of revenue per employee.
Data provided by Twelve Data
The nearest names by industry and size, scored by the same model — like for like.
Look up any of the roughly 4,600 stocks we score.
The rank is the raw material. Whether the rules would actually own Guardant Health, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →
Zacks Investment Research says Guardant Health has the combination of factors it views as supporting a likely earnings beat in the upcoming Q3 report, and outlines key expectations ahead of the release.
Why it matters — The item previews expectations for GH’s upcoming Q3 earnings report.
Guardant Health applauded Pennsylvania’s enactment of HB 1123, which aligns colorectal cancer screening insurance coverage with updated ACS and NCCN guidelines. The law ensures no cost-sharing for screening for about 2 million Pennsylvanians of screening-eligible age.
Why it matters — GH watchers may note the law’s potential relevance to access to colorectal cancer screening innovations in Pennsylvania.
The excerpt says several key approvals and coverage expansions supported product growth for Guardant Health during the quarter.
Why it matters — Approvals and expanded coverage were cited as factors supporting GH's product growth.
Benzinga’s headline reports that an analyst began coverage of Guardant Health with a bullish note. The excerpt provides no further details about the analyst or the coverage.
Why it matters — A new bullish analyst initiation is a relevant change in the Wall Street outlook for GH.
Guardant Health and its research collaborators will present 25 abstracts, including five rapid oral presentations, at the ESMO Congress 2026. The research covers methylation-based ctDNA monitoring and liquid biopsy technology in lung, colorectal, and gastric cancers.
Why it matters — The presentations highlight the breadth of Guardant Health’s oncology research and liquid biopsy work across several cancer types.
The 26 Wall Street analysts covering Guardant Health, Inc. have a median 12-month price target of $203, with estimates ranging from $105 to $240. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.
Of the 26 analysts covering Guardant Health, Inc., 25 rate it a Buy, 0 a Hold and 1 a Sell. Ticker Nerd's systematic factor model ranks Guardant Health, Inc. 57 out of 100 across roughly 4,600 US stocks as at 28 Oct 2026. None of this is personal advice — it does not consider your circumstances.
As at 28 Oct 2026, Guardant Health, Inc. ranks 57 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Momentum (100 of 100).
No one can know that. What the data says: the median 12-month target from 26 analysts implies +9.5% from the last close, and Ticker Nerd's factor model ranks Guardant Health, Inc. 57 out of 100 as at 28 Oct 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.
No analyst covering Guardant Health, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for GH are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $105 to $240 over the next 12 months.
Guardant Health, Inc. returned +156.4% over the 12 months to 29 Oct 2026, with dividends reinvested. Past performance does not indicate future returns.
Guardant Health, Inc. is a precision oncology company that develops blood- and tissue-based diagnostic tests, data solutions, and analytics for cancer care.
The most recent item we track (Zacks Investment Research, 29 Oct 2026): "Guardant Health (GH) Expected to Beat Earnings Estimates: What to Know Ahead of Q3 Release". Zacks Investment Research says Guardant Health has the combination of factors it views as supporting a likely earnings beat in the upcoming Q3 report, and outlines key expectations ahead of the release.
Guardant Health, Inc. is a precision oncology company that develops blood- and tissue-based diagnostic tests, data solutions, and analytics for cancer care. Its offerings support multiple stages of the oncology pathway, including screening for colorectal cancer, molecular profiling of tumors, treatment selection, monitoring for residual disease and recurrence, and research into tumor biology and therapeutic response. Products such as Guardant360, Guardant Reveal, Guardant360 Tissue, and Shield provide clinicians and researchers with genomic, epigenomic, transcriptomic, and circulating tumor DNA insights. The company also serves biopharmaceutical organizations through companion diagnostic development, clinical testing services, technology licensing, and real-world data solutions. Its software and data platforms help connect molecular findings with clinical outcomes and relevant research opportunities. Headquartered in Palo Alto, California, Guardant Health, Inc. operates across healthcare, biotechnology, clinical diagnostics, and biopharmaceutical markets, contributing to the broader use of precision medicine in cancer prevention, diagnosis, treatment, and monitoring.
CEO Dr. Helmy Eltoukhy Ph.D. · 2,490 employees · United States · https://guardanthealth.com
